Pfizer Inc. (PFE) filed a Form 8K - Changes in Company Executive
Management - with the U.S Securities and Exchange Commission on
February 10, 2014.
On February 10, 2014, Esperion Therapeutics, Inc. (the
"Company") elected Mark E. McGovern, M.D., to the Board of
Directors of the Company. Dr. McGovern was elected as a Class I
director and will serve until the Company's annual meeting of
stockholders in 2014 or until his successor is duly elected and
qualified.
Dr. McGovern is a board-certified cardiologist with over 20
years of experience developing lipid regulating therapies, and
since 2007, has served as a consultant to the pharmaceutical
industry in cardiovascular and lipid regulation. Dr. McGovern's
experience includes 11 years at Bristol-Myers Squibb (NYSE: BMY),
from 1986 to 1997, in various capacities, including Executive
Director, Heart Failure and Atherosclerosis Clinical Research. Dr.
McGovern subsequently spent 10 years, from 1997 to 2007, at Kos
Pharmaceuticals, where he last served as executive vice president,
medical affairs, and chief medical officer, prior to its
acquisition by Abbott Laboratories. Dr. McGovern earned his
Bachelor's degree summa cum laude from Princeton University and his
medical degree from the University of Vermont. Dr. McGovern is a
Fellow of the American College of Cardiology and the American
College of Physicians, and has published extensively on lipid
management and its role in the treatment of coronary heart disease.
The Company believes that Dr. McGovern is qualified to serve as a
director based on his broad experience in the industry in which it
operates.
As a non-employee director, Dr. McGovern will receive cash and
equity compensation paid by the Company pursuant to its
non-employee director compensation program. There are no
arrangements or understandings between Dr. McGovern and any other
person pursuant to which Dr. McGovern was selected as a director,
and there are no transactions between Dr. McGovern and the Company
that would require disclosure under Item 404(a) of Regulation
S-K.
* * *
The full text of this SEC filing can be retrieved at:
http://www.sec.gov/Archives/edgar/data/1434868/000110465914010650/a14-5895_18k.htm
Any exhibits and associated documents for this SEC filing can be
retrieved at:
http://www.sec.gov/Archives/edgar/data/1434868/000110465914010650/0001104659-14-010650-index.htm
Public companies must file a Form 8-K, or current report, with
the SEC generally within four days of any event that could
materially affect a company's financial position or the value of
its shares.
Subscribe to WSJ: http://online.wsj.com?mod=djnwires